Annals of Hematology

, Volume 90, Issue 1, pp 41–46 | Cite as

Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase

  • Hao Jiang
  • Shan-Shan Chen
  • Bin Jiang
  • Qian Jiang
  • Ya-Zhen Qin
  • Yue-Yun Lai
  • Xiao-Jun Huang
Original Article

Abstract

The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment in Chinese patients with chronic myelogenous leukemia-chronic phase (CML-CP) patients in a single center in Beijing. A retrospective study of 171 CML-CP patients receiving imatinib monotherapy was done with 73 in the initial treatment group (disease course ≤6 months) and 98 in the re-treatment group (disease course >6 months). Cumulative rates of complete cytogenetic response (CCyR) at 6, 12, and 36 months after imatinib treatment in the initial and re-treatment groups were 75%, 89%, and 96%, and 48%, 77% and 84% (p = 0.0002), respectively. The median time to CCyR in the initial and re-treatment groups was 6 months (95% CI, 3.3–8.3) and 9 months (95% CI, 6.4–11.6), respectively (p = 0.0002). Cumulative rates of major molecular responses at 9, 12, and 18 months after imatinib treatment in the initial and re-treatment groups were 31%, 48%, and 60%, and 15%, 25% and 37% (p = 0.017), respectively. The median time to the major molecular response in the initial and re-treatment groups was 15 months (95% CI, 12.3–17.7) and 36 months (95% CI, 25.9–46.0), respectively (p = 0.017). Progression-free survival at 84 months in the initial and re-treatment groups was 97% and 85%, respectively (p = 0.09). Event-free survival at 84 months in the initial and re-treatment groups was 92% and 70%, respectively (p = 0.049). Only two of the 171 patients discontinued imatinib therapy for grade 3/4 adverse events. Our study revealed that CML-CP patients would benefit from early treatment with imatinib.

Keywords

Chronic myeloid leukemia Imatinib Cytogenetic response Molecular response Event-free survival 

Notes

Acknowledgments

The authors would like to thank the contributions of all the people who have participated in this research. This includes our laboratory staff, our colleagues, and our nurses. During April 2001 to April 2002, 46 patients in our study had enrolled in the international phase II expanded clinical trial of imatinib mesylate sponsored by Novartis. Imatinib for patients for 9 months every year was supplied by the Glivec International Patient Assistance Program (Novartis)—patients paid for the other 3 months each year themselves.

Funding

Supported by the program for innovative research team in the university (grant No. IRT 0702)

Authorship and Disclosures

JH, CSS, JB, and JQ received research grants from Novartis in the course of the international phase II expanded clinical trial of imatinib mesylate in China from April 2001 to April 2002. All other authors declare no competing financial interests. HXJ takes responsibility for the paper. JH, CSS, JB, and JQ recruited the patients. QYZ and LYY performed the laboratory work for this study. HXJ and JH coordinated the research. JH participated in the statistical analysis. HXJ and JH wrote the paper.

References

  1. 1.
    Goldman JM, Melo JV (2003) Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 349:1451–1464CrossRefPubMedGoogle Scholar
  2. 2.
    Druker BJ, Lydon NB (2000) Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7CrossRefPubMedGoogle Scholar
  3. 3.
    Hochhaus A, Druker BJ, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al (2008) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-treatment. Blood 111(3):1039–1043CrossRefPubMedGoogle Scholar
  4. 4.
    Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417CrossRefPubMedGoogle Scholar
  5. 5.
    Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037CrossRefPubMedGoogle Scholar
  6. 6.
    Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530–3539CrossRefPubMedGoogle Scholar
  7. 7.
    Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928–1937CrossRefPubMedGoogle Scholar
  8. 8.
    Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652CrossRefPubMedGoogle Scholar
  9. 9.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004CrossRefPubMedGoogle Scholar
  10. 10.
    Jiang H, Chen S, Jiang B, Jiang Q, Lu D et al (2003) Imatinib in the treatment of 54 cases of Ph-positive chronic myeloid leukemia. Chin J Hematol 24:281–285Google Scholar
  11. 11.
    NCCN Practice Guidelines in Oncology-v.3.2008. http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf
  12. 12.
    Hong H, Qiu J, Lai Y, Shi Y, He Q, Dang H et al (2003) Cytogenetic analysis of interferon-α in the treatment of Ph+ chronic myeloid leukemia. Chin J Exp Hematol 3:269–273Google Scholar
  13. 13.
    Qin Y, Li J, Zhu H, Ruan G, Li L, Zhang Y et al (2006) The level of bcr-abl mRNA monitored by real-time quantitative RT-PCR in patients with chronic myeloid leukemia after hematopoietic stem cell transplantation. Chin J Hematol 8:511–514Google Scholar
  14. 14.
    O’Brien SG (2004) Optimal therapy in CML. Am Soc Hematol Educ Program 146–149Google Scholar
  15. 15.
    Apperley JF (2003) Managing CML with patient-specific strategies. Am Soc Hematol Educ Program 142–152Google Scholar
  16. 16.
    Shah NP (2005) Loss of response to imatinib: mechanisms and management. Am Soc Hematol Educ Program 183–187Google Scholar
  17. 17.
    Hochhaus A, Druker BJ, Larson RA, O’Brien SG, Gathmann I, Guilhot F et al (2007) IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 110(11) (abstr 25)Google Scholar
  18. 18.
    Goldman JM, Hughes T, Radichet J, Branford S, Hochhaus A, So C et al (2005) Continuing reduction in level of residual disease after 4 years in patients with CML in chronic phase responding to first-line imatinib (IM) in the IRIS Study. Blood (ASH Annual Meeting Abstracts) 106(11) (abstr 163)Google Scholar
  19. 19.
    Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074–3081CrossRefPubMedGoogle Scholar
  20. 20.
    Kantarjian HM, O’Brien S, Cortes JE, Shan JQ, Giles FJ, Rios MB et al (2003) Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033–1041CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Hao Jiang
    • 1
  • Shan-Shan Chen
    • 1
  • Bin Jiang
    • 1
  • Qian Jiang
    • 1
  • Ya-Zhen Qin
    • 1
  • Yue-Yun Lai
    • 1
  • Xiao-Jun Huang
    • 1
  1. 1.The Institute of HematologyPeople’s Hospital of Peking UniversityBeijingChina

Personalised recommendations